AOD-9604: Dosing Protocols

Research Dosing Disclaimer#

Clinical Trial Dosing History#

AOD-9604 has the most extensive clinical dosing history of any non-approved peptide discussed on this site, having been tested in over 900 human participants across six clinical trials. All human clinical trials used oral administration.

Phase I Dose Escalation#

Phase I studies established safety across a range of oral doses. AOD-9604 was well tolerated with no dose-limiting toxicities identified. Key safety parameters monitored included:

• Serum IGF-1 levels (unchanged at all doses)
• Oral glucose tolerance (unaffected)
• Hormonal panels (thyroid, adrenal, gonadal -- all unchanged)

Phase IIa Trial Dosing#

The 12-week Phase IIa trial used oral AOD-9604 at 1 mg/day. This dose produced an average weight loss of 2.6 kg compared to 0.8 kg for placebo (a difference of approximately 1.8 kg). While statistically significant, this magnitude of weight loss was modest.

Phase IIb OPTIONS Study Dosing#

The pivotal 24-week Phase IIb trial tested lower oral doses than the Phase IIa study, based on dose-ranging considerations. Despite 536 participants and 24 weeks of treatment, the study failed to demonstrate statistically significant weight loss compared to placebo.

The failure may have been partly attributable to insufficient oral bioavailability at the tested doses.

Route of Administration Considerations#

Oral Administration#

All human clinical trial data used oral dosing. Oral peptide delivery is inherently challenging due to:

• Gastric acid degradation
• Enzymatic hydrolysis by GI proteases
• Poor intestinal absorption of peptides
• First-pass hepatic metabolism

However, AOD-9604's disulfide-bonded cyclic structure may confer partial resistance to proteolytic degradation, which could explain the modest oral efficacy observed in preclinical studies using oral dosing.

Subcutaneous Injection#

Subcutaneous injection bypasses the gastrointestinal barriers to peptide delivery and is the most common route for research-grade peptide administration. While no controlled human clinical data exists for subcutaneous AOD-9604, this route would theoretically provide:

• Higher bioavailability than oral dosing
• More predictable pharmacokinetics
• Potentially lower required doses

Common subcutaneous research protocols suggest doses of 250-300 mcg per day, administered in the morning before eating. These doses are derived from anecdotal research experience rather than controlled dose-finding studies.

Intra-Articular Injection#

For cartilage repair research, direct intra-articular injection delivers AOD-9604 to the target tissue at high local concentrations while minimizing systemic exposure. The only published preclinical data used 0.25 mg AOD-9604 per weekly injection in rabbit joints (PMID: 26275694).

Research Dosing Summary#

Reconstitution and Preparation#

Standard Reconstitution Protocol#

1. Remove the cap from the AOD-9604 lyophilized vial
2. Clean the rubber stopper with an alcohol swab
3. Draw up the appropriate volume of bacteriostatic water (0.9% benzyl alcohol)
4. Insert the needle through the stopper and slowly inject the water down the side of the vial
5. Gently swirl (do not shake) until fully dissolved
6. The solution should be clear and colorless
7. If particulate matter is visible, do not use

Concentration Table#

Subcutaneous Injection Technique#

For subcutaneous research use:

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin at the injection site
3. Insert a 29-31 gauge needle at a 45-degree angle
4. Inject slowly
5. Release the skin fold and withdraw the needle
6. Apply gentle pressure with a cotton ball

Timing Considerations#

In research protocols, AOD-9604 is typically administered in the morning on an empty stomach (at least 30 minutes before eating). This timing is based on the rationale that:

• Fasting state may enhance lipolytic signaling
• Morning administration aligns with the natural diurnal pattern of lipolysis
• Food intake may interfere with absorption (particularly for oral dosing)

However, these timing recommendations are based on theoretical rationale rather than controlled pharmacokinetic studies.

Storage and Handling#

Lyophilized Powder#

• Store at -20 degrees Celsius
• Keep sealed and desiccated
• Protect from light
• Stable for 12+ months when properly stored

Reconstituted Solution#

• Refrigerate at 2-8 degrees Celsius
• Use within 4 weeks of reconstitution
• Do not freeze
• Protect from light
• Inspect for particulates before each use

Special Handling Notes#

The disulfide bond between Cys7 and Cys14 is essential for biological activity. This bond can be disrupted by:

• Strong reducing agents (DTT, beta-mercaptoethanol)
• Alkaline pH (>8.0)
• Excessive heat
• Vigorous shaking

Degradation of the disulfide bond may not be visually apparent, making proper storage conditions particularly important.

Evidence Gaps#

• No dose-finding studies for subcutaneous administration in humans
• Oral bioavailability not quantified; relationship between oral dose and systemic exposure unknown
• Optimal dosing for cartilage repair applications not established
• Duration of treatment needed for cartilage effects not studied in any species
• Timing of administration (fasting vs fed state) not systematically evaluated
• Safety of long-term continuous administration (>24 weeks) not established

Related Reading#

• AOD-9604 overview and research guide
• AOD-9604 side effects profile
• AOD-9604 research evidence